

高雄榮民總醫院 子宮惡性肉瘤診療指引

2019年01月22日第一版

婦癌醫療團隊擬訂

注意事項：這個診療原則主要作為醫師和其他保健專家診療癌症病人參考之用。假如你是一個癌症病人，直接引用這個診療原則並不恰當，只有你的醫師才能決定給你最恰當的治療。

修訂指引

- 本共識依下列參考資料修改版本
 - NCCN Clinical Practical Guidelines in Oncology™ Uterine Sarcoma Cancer (Version 1.2018 — October 13, 2017)
 - 婦癌研究委員會，子宮惡性肉瘤癌篩檢臨床指引（2011）：國家衛生研究院
 - 其他相關子宮惡性肉瘤臨床指引

會議討論

上次會議：2018/05/15

本共識與上一版的差異

上一版	新版
<p>1. 診療指引中陳列之Paclitaxel+ Cisplatin/Carboplatin化療處方線上未建置。(p. 16)</p> <p>2. 線上建置之荷爾蒙藥物Pazopanib (Votrient)200mg, 4#, ODAC與 Letrozole(Femara)2.5mg, 1#, QD 處方未陳列診療指引中。(p. 16)</p>	<p>1. 刪除線上未建置之Paclitaxel+ Cisplatin/Carboplatin化療處方。(p. 16)</p> <p>2. 將線上建置之荷爾蒙藥物Pazopanib (Votrient)200mg, 4#, ODAC與 Letrozole(Femara)2.5mg, 1#, QD 處方增列於診療指引。(p. 16)</p>

高雄榮總婦癌團隊子宮惡性肉瘤臨床診療指引

分期AJCC 8th

Corpus Uteri – Carcinoma and Carcinosarcoma

Primary Tumor (T)		
T	FIGO	T Criteria
TX		Primary tumor cannot be assessed
T0		No evidence of primary tumor
T1	I	Tumor confined to the corpus uteri, including endocervical glandular involvement
T1a	IA	Tumor limited to the endometrium or invading less than half the myometrium
T1b	IB	Tumor invading one half or more of the myometrium
T2	II	Tumor invading the stromal connective tissue of the cervix but not extending beyond the uterus. Does NOT include endocervical glandular involvement.
T3	III	Tumor involving serosa, adnexa, vagina, or parametrium
T3a	IIIA	Tumor involving the serosa and/or adnexa (direct extension or metastasis)
T3b	IIIB	Vaginal involvement (direct extension or metastasis) or parametrial involvement
T4	IVA	Tumor invading the bladder mucosa and/or bowel mucosa (bullous edema is not sufficient to classify a tumor as T4)

Regional Lymph Node (N)		
N	FIGO	N Criteria
NX		Regional lymph nodes cannot be assessed
N0		No regional lymph node metastasis
N0 (i+)		Isolated tumor cells in regional lymph node(s) no greater than 0.2 mm
N1	IIIC1	Regional lymph nodes metastasis to pelvic lymph nodes
N1mi	IIIC1	Regional lymph node metastasis (greater than 0.2 mm but not greater than 2.0 mm in diameter) to pelvic lymph nodes
N1a	IIIC1	Regional lymph node metastasis (greater than 2.0 mm in diameter) to pelvic lymph nodes
N2	IIIC2	Regional lymph node metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes
N2mi	IIIC2	Regional lymph node metastasis (greater than 0.2 mm but not greater than 2.0 mm in diameter) to para-aortic lymph nodes, with or without positive pelvic lymph nodes
N2a	IIIC2	Regional lymph node metastasis (greater than 2.0 mm in diameter) to para-aortic lymph nodes, with or without positive pelvic lymph nodes

分期AJCC 8th

Corpus Uteri – Carcinoma and Carcinosarcoma

Distant Metastasis (M)		
M	FIGO	M Criteria
M0		No distant metastasis
M1	IVB	Distant metastasis (includes metastasis to inguinal lymph nodes, intraperitoneal disease, lung, liver, or bone). (It excludes metastasis to pelvic or para-aortic lymph nodes, vagina, uterine serosa, or adnexa).

STAGE GROUPS			
T	N	M	stage
T1	N0	M0	I
T1a	N0	M0	IA
T1b	N0	M0	IIB
T2	N0	M0	II
T3	N0	M0	III
T3a	N0	M0	IIIA
T3b	N0	M0	IIIB
T1-T3	N1/N1mi/N1a	M0	IIIC1
T1-T3	N2/N2mi/N2a	M0	IIIC2
T4	Any N	M0	IVA
Any T	Any N	M1	IVB

高雄榮總婦癌團隊子宮惡性肉瘤臨床診療指引

分期AJCC 8th

Corpus Uteri – Sarcoma

Leiomyosarcoma and Endometrial Stromal Sarcoma		
Primary Tumor (T)		
T	FIGO	T Criteria
TX		Primary tumor cannot be assessed
T0		No evidence of primary tumor
T1	I	Tumor limited to the uterus
T1a	IA	Tumor 5 cm or less in greatest dimension
T1b	IB	Tumor more than 5 cm
T2	II	Tumor extends beyond the uterus, within the pelvis
T2a	IIA	Tumor involves adnexa
T2b	IIB	Tumor involves other pelvic tissues
T3	III	Tumor infiltrates abdominal tissues
T3a	IIIA	One site
T3b	IIIB	More than one site
T4	IVA	Tumor invades bladder or rectum

Adenosarcoma		
Primary Tumor (T)		
T	FIGO	T Criteria
TX		Primary tumor cannot be assessed
T0		No evidence of primary tumor
T1	I	Tumor limited to the uterus
T1a	IA	Tumor limited to the endometrium/endocervix
T1b	IB	Tumor invades to less than half of the myometrium
T1c	IC	Tumor invades more than half of the myometrium
T2	II	Tumor extends beyond the uterus, within the pelvis
T2a	IIA	Tumor involves adnexa
T2b	IIB	Tumor involves other pelvic tissues
T3	III	Tumor infiltrates abdominal tissues
T3a	IIIA	One site
T3b	IIIB	More than one site
T4	IVA	Tumor invades bladder or rectum

Regional Lymph Node (N)		
All Uterine Sarcomas		
N	FIGO	N Criteria
NX		Regional lymph nodes cannot be assessed
N0		No regional lymph node metastasis
N0 (i+)		Isolated tumor cells in regional lymph node(s) node(s) no greater than 0.2 mm
N1	IIIC	Regional lymph nodes metastasis

高雄榮總婦癌團隊子宮惡性肉瘤臨床診療指引

分期AJCC 8th

Corpus Uteri – Sarcoma

Distant Metastasis (M)		
All Uterine Sarcomas		
M	FIGO	M Criteria
M0		No distant metastasis
M1	IVB	Distant metastasis (excluding adnexa, pelvic, and abdominal tissues)

Leiomyosarcoma and Endometrial Stromal Sarcoma			
STAGE GROUPS			
T	N	M	stage
T1	N0	M0	I
T1a	N0	M0	IA
T1b	N0	M0	IB
T1c	N0	M0	IC
T2	N0	M0	II
T3a	N0	M0	IIIA
T3b	N0	M0	IIIB
T1-3	N1	M0	IIIC
T4	Any N	M0	IVA
Any-T	Any N	M1	IVB

Adenosarcoma			
STAGE GROUPS			
T	N	M	stage
T1	N0	M0	I
T1a	N0	M0	IA
T1b	N0	M0	IB
T2	N0	M0	II
T3a	N0	M0	IIIA
T3b	N0	M0	IIIB
T1-3	N1	M0	IIIC
T4	Any N	M0	IVA
Any-T	Any N	M1	IVB

子宮惡性肉瘤診療指引相關之主要檢查


1. 病史
2. 理學檢查及一般婦科基本檢查: 內診/抹片/婦科超音波
3. 子宮鏡檢查、子宮內膜及子宮內頸切片檢查(報告)*
4. CXR, ECG
5. CBC/DC, SMA
6. Pelvic/Abdominal MRI or CT, Chest CT scan, Tumor markers ** :
LDH, Ca-125, Ca-199, CEA.
7. PET-CT**
8. Bone scan ***
9. Pelvic CT scan, Chest CT scan, Brain CT/MRI***

*當手術後意外發現(診斷)時無需檢查或外院病理複閱

**可做為首次/追蹤/複發檢查

***做為追蹤/複發檢查


高雄榮總婦癌團隊子宮惡性肉瘤臨床診療指引



- 術前影像學和切片可能有助於確定子宮肉瘤，雖然切片靈敏度小於子宮內膜癌。如果有基質惡性肉瘤的嫌疑，腫瘤片段取出應該避免。
- 除非有禁忌，電腦斷層或磁共振造影的對比要遵循準則。
- 卵巢摘除會因病人是否為已進入更年期而考慮。但如果ER/PR positive則建議BSO。
- 對於經TH/BSO或切片標本後發現子宮肉瘤：建議依個人狀態進行影像及額外的手術切除
- 子宮惡性肉瘤應該整塊移除以獲取最佳結果；取出時應避免分碎組織

流程圖一


高雄榮總婦癌團隊子宮惡性肉瘤臨床診療指引



§ 尤其停經或BSO或使用雌激素抑制劑

流程圖二

高雄榮總婦癌團隊子宮惡性肉瘤臨床診療指引



流程圖三

高雄榮總婦癌團隊子宮惡性肉瘤臨床診療指引

追蹤表

- 前二-三年，每三-四個月，之後每6-12個月身體檢查
- 術後第1-3年，因病情需要每3-6個月，可使用電腦斷層檢查胸/腹/骨盆腔部位，第4-5年，因病情需要每6月行電腦斷層檢查，第6年以後每一年行上述電腦斷層檢查
- 因病情或臨床上有轉移之可能使用核磁共振或正子檢查
- 給予病人病情詳細衛教及說明

局部復發
 ●陰道/骨盆腔
 ●胸部x光正常及電腦斷層腹部及骨盆腔檢查，僅局部陰道/骨盆腔復發

僅單獨一處轉移

多處轉移

可切除

不可切除

治療見復發表


考慮外科手術切除或其他局部熱頻燒灼治療(RFA: Radiofrequency Ablation): 考慮術後全身系統性治療(化療/標靶/荷爾蒙)蒙此僅對子宮內膜基質惡性肉瘤) 或 術後放射線治療

*全身系統性治療(化療/標靶/荷爾蒙)±緩和放射線治療(之後若可切除病灶，可考慮手術) 或其他局部熱頻燒灼治療(RFA: Radiofrequency Ablation) 或 緩解放射線治療 若有好的效果可考慮手術

全身系統性治療(化療/標靶/荷爾蒙)±緩解放射線治療或最好支持療法

流程圖四

高雄榮總婦癌團隊子宮惡性肉瘤臨床診療指引



*手術中行病灶放射線治療(IORT)目前在本科未有此項服務。

流程圖五

子宮惡性肉瘤分類

UTERINE SARCOMA CLASSIFICATION¹

- Low-grade endometrial stromal sarcoma (ESS)²
- High-grade ESS³
- Undifferentiated uterine sarcoma (UUS)⁴
- Uterine leiomyosarcoma (uLMS)⁵

Other Rare Uterine Mesenchymal Sarcoma Subtypes:
(see the [NCCN Guidelines for Soft Tissue Sarcoma](#))

- Adenosarcomas
- PEComas
- Rhabdomyosarcoma

Adjuvant /or Salvage 化學治療(輔助或轉移)

protocol	劑量	時程
Decarbazine,(DTIC) Epirubicin, Platinum, Ifosfamide	Dacarbazine 200mg qd x 5 days Epirubicin 50mg/m ² st Carboplatin AUC x5mg st, CCR < 60 (Cisplatin 50mg/m ² st, CCR ≥ 60) Ifosfamide 4mg/m ² st	Q3W x 6 cycles (1)
Gemcitabine+Docetaxel	D1/D8 Gemcitabine 675-900 mg/m ² D8 Docetaxel 75-100 mg/m ²	Q4W x 6 cycles (2)
荷爾蒙治療		
Pazopanib(Votrient) 200mg,4#,ODAC (3)		
Letrozole(Femara) 2.5mg,1#,QD (4)		

PRINCIPLES OF IMAGING
(References)

- ¹Salani R, Khanna N, Frimer M, et al. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. *Gynecol Oncol* 2017;146:3-10.
- ²Haldorsen IS, Salvesen HB. What is the best preoperative imaging for endometrial cancer? *Curr Oncol Rep* 2016 Apr;18(4):25.
- ³Elit L, Reade CJ. Recommendations for follow-up care for gynecologic cancer survivors. *Obstet Gynecol* 2015 Dec;126 (6):1207-1214.
- ⁴Vargas HA, Akin O, Zheng J, et al. The value of MR imaging when the site of uterine cancer origin is uncertain. *Radiology* 2011 Mar;258(3):785-792.
- ⁵Sohaib SA, Houghton SL, Meroni R, et al. Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis. *Clin Radiol* 2007 Jan;62(1):28-34; discussion 35-36.
- ⁶Hensley ML, Barrette BA, Baumann K, et al. Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas. *Int J Gynecol Cancer* 2014 Nov;24(9 Suppl 3):S61-66.
- ⁷Lakhman Y, Katz SS, Goldman DA, et al. Diagnostic Performance of Computed Tomography for Preoperative Staging of Patients with Non-endometrioid Carcinomas of the Uterine Corpus. *Ann Surg Oncol* 2016 Apr;23(4):1271-1278.
- ⁸Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. *Ann Oncol* 2016 Jan;27(1):16-41.
- ⁹Sala E, Rockall AG, Freeman SJ, et al. The added role of MR imaging in treatment stratification of patients with gynecologic malignancies: what the radiologist needs to know. *Radiology* 2013 Mar;266(3):717-740.

PRINCIPLES OF RADIATION THERAPY FOR UTERINE NEOPLASMS

- RT is directed at sites of known or suspected tumor involvement and may include external beam RT (EBRT) and/or brachytherapy. Imaging is required to assess locoregional extent and to rule out distant metastases before administration of RT. In general, EBRT is directed to the pelvis with or without the para-aortic region. Brachytherapy can be delivered: 1) to an intact uterus, either preoperatively or definitively; or 2) more commonly, to the vagina after hysterectomy. For the purposes of these guidelines, whole abdominal radiotherapy is not considered to be tumor-directed RT.
- For neoadjuvant radiation or radiation after resection of gross disease, doses of 45-50 Gy are typically used. One could consider adding 1-2 high dose rate (HDR) insertions to a total dose of 75 to 80 Gy low-dose-rate equivalent. For neoadjuvant treatment to minimize risk of positive or close margins at hysterectomy.
- Pelvic radiotherapy should target the gross disease (if present), the lower common iliacs, external iliacs, internal iliacs, parametria, upper vagina/para-vaginal tissue, and presacral lymph nodes (in patients with cervical involvement). Extended-field radiotherapy should include the pelvic volume and also target the entire common iliac chain and para-aortic lymph node region. The upper border of the extended field depends on the clinical situation but should at least be 1-2 cm above the level of the renal vessels. External-beam doses for microscopic disease should be 45 to 50 Gy. Multiple conformal fields based on CT-treatment planning should be utilized, and consideration for IMRT for normal tissue sparing may be considered, with appropriate attention to QA and tissue interfraction mobility.
- Initiate brachytherapy as soon as the vaginal cuff is healed, preferably 6- 8 weeks after surgery but in general initiation of brachytherapy should not exceed 12 weeks. For vaginal brachytherapy, the dose should be prescribed to the vaginal surface or at a depth of 0.5 cm from the vaginal surface; the dose depends on the use of EBRT. The target for vaginal brachytherapy after hysterectomy should be no more than the upper two-thirds of the vagina; in cases of extensive LVSI or positive margins, a longer segment of the vagina may be treated.
 - ▶ For postoperative high-dose-rate vaginal brachytherapy preferred regimens include 6 Gy X 5 fractions prescribed to the vaginal surface, or 5.5 Gy X 4 prescribed to 5 mm below the vaginal surface. While 7 Gy x 3 prescribed at a depth of 0.5 cm from the vaginal surface is a regimen used by many, studies suggest there may be increased toxicity.
 - ▶ When high-dose-rate brachytherapy is used as a boost to EBRT, doses of 4 to 6 Gy x 2 to 3 fractions prescribed to the vaginal mucosa are commonly used.
- For medically inoperable uterine cancer, risk of extrauterine spread determines the combination of external beam plus brachytherapy or brachytherapy alone. Brachytherapy doses for definitive therapy are individualized based on the clinical situation. When available, image-guided therapy should be used. Based on the best available evidence, an EQD2 D90 of at least 48 Gy should be delivered to the uterus, cervix and upper 1-2 cm of vagina if brachytherapy alone is used, and should be increased to 65 Gy for the combination of external beam and brachytherapy. If an MRI is used as part of planning, the target dose for the GTV would be an EQD2 of ≥ 80 Gy.
- Evidence supports the use of combined modality radiation and chemotherapy as adjuvant treatment for patients with extrauterine disease.

Reference

1. Pautier P, Genestie C, Fizazi K, Morice P, Haie-Meder C, Le Cesne A, Lhommé C; Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcoma. *Int J Gynecol Cancer*. 2002 Nov-Dec; 12(6): 749-54.
2. Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghahanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR; Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. *J Clin Oncol*. 2002 Jun 15; 20(12):2824-31.
3. Kim HJ, Kim Y, Lee SJ, Lee J, Park SH; Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study. *J Gynecol Oncol*. 2018 Jan; 29(1):e3.
4. George S, Feng Y, Manola J, Nucci MR, Butrynski JE, Morgan JA, Ramaiya N, Quek R, Penson RT, Wagner AJ, Harmon D, Demetri GD, Krasner C; Phase 2 trial of aromatase inhibitor with letrozole in patients with uterine leiomyosarcomas expressing estrogen and /or progesterone receptors. *Cancer*. 2014 Mar 1; 120(5): 738-43.

321. Trope CG, Abeler VM, Kristensen GB. Diagnosis and treatment of sarcoma of the uterus. A review. *Acta Oncol* 2012;51:694-705. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22793037>.
322. Amant F, Coosemans A, Debiec-Rychter M, et al. Clinical management of uterine sarcomas. *Lancet Oncol* 2009;10:1188-1198. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19959075>.
323. Novetsky AP, Powell MA. Management of sarcomas of the uterus. *Curr Opin Oncol* 2013;25:546-552. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23942299>.
324. Lax SF. Molecular genetic changes in epithelial, stromal and mixed neoplasms of the endometrium. *Pathology* 2007;39:46-54. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17365822>.
325. Huang HY, Ladanyi M, Soslow RA. Molecular detection of JAZF1-JJAZ1 gene fusion in endometrial stromal neoplasms with classic and variant histology: evidence for genetic heterogeneity. *Am J Surg Pathol* 2004;28:224-232. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15043312>.
326. Leath CA, 3rd, Huh WK, Hyde J, Jr., et al. A multi-institutional review of outcomes of endometrial stromal sarcoma. *Gynecol Oncol* 2007;105:630-634. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17320937>.
327. Koontz JI, Soreng AL, Nucci M, et al. Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. *Proc Natl Acad Sci U S A* 2001;98:6348-6353. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11371647>.
328. Lee CH, Marino-Enriquez A, Ou W, et al. The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor. *Am J Surg Pathol* 2012;36:641-653. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22456610>.
329. Sciallis AP, Bedroske PP, Schoolmeester JK, et al. High-grade endometrial stromal sarcomas: a clinicopathologic study of a group of tumors with heterogenous morphologic and genetic features. *Am J Surg Pathol* 2014;38:1161-1172. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25133706>.
330. Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO Classification of Tumours of Female Reproductive Organs. Fourth Edition. Vol. 6: World Health Organization; 2014.
331. Zivanovic O, Leitao MM, Iasonos A, et al. Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems. *J Clin Oncol* 2009;27:2066-2072. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19255317>.
332. Prat J. FIGO staging for uterine sarcomas. *Int J Gynaecol Obstet* 2009;104:177-178. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19135669>.
333. Rauh-Hain JA, del Carmen MG. Endometrial stromal sarcoma: a systematic review. *Obstet Gynecol* 2013;122:676-683. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23921879>.
334. Group EESNW. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2012;23 Suppl 7:vii92-99. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22997462>.
335. Barney B, Tward JD, Skidmore T, Gaffney DK. Does radiotherapy or lymphadenectomy improve survival in endometrial stromal sarcoma? *Int J Gynecol Cancer* 2009;19:1232-1238. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19823060>.
336. Shah JP, Bryant CS, Kumar S, et al. Lymphadenectomy and ovarian preservation in low-grade endometrial stromal sarcoma. *Obstet Gynecol* 2008;112:1102-1108. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18978112>.

337. Signorelli M, Fruscio R, Dell'Anna T, et al. Lymphadenectomy in uterine low-grade endometrial stromal sarcoma: an analysis of 19 cases and a literature review. *Int J Gynecol Cancer* 2010;20:1363-1366. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21051978>.
338. Reichardt P. The treatment of uterine sarcomas. *Ann Oncol* 2012;23 Suppl 10:x151-157. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22987952>.
339. Thanopoulou E, Judson I. Hormonal therapy in gynecological sarcomas. *Expert Rev Anticancer Ther* 2012;12:885-894. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22845404>.
340. Pink D, Lindner T, Mrozek A, et al. Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. *Gynecol Oncol* 2006;101:464-469. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16368128>.
341. Reich O, Regauer S. Estrogen replacement therapy and tamoxifen are contraindicated in patients with endometrial stromal sarcoma. *Gynecol Oncol* 2006;102:413-414; author reply 414. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16712906>.
342. Mansi JL, Ramachandra S, Wiltshaw E, Fisher C. Endometrial stromal sarcomas. *Gynecol Oncol* 1990;36:113-118. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2295442>.
343. Berchuck A, Rubin SC, Hoskins WJ, et al. Treatment of endometrial stromal tumors. *Gynecol Oncol* 1990;36:60-65. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2295453>.
344. Weitmann HD, Knocke TH, Kucera H, Pötter R. Radiation therapy in the treatment of endometrial stromal sarcoma. *Int J Radiat Oncol Biol Phys* 2001;49:739-748. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11172957>.
345. Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. *N Engl J Med* 2007;357:2277-2284. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18046031>.
346. Sampath S, Schultheiss TE, Ryu JK, Wong JY. The role of adjuvant radiation in uterine sarcomas. *Int J Radiat Oncol Biol Phys* 2010;76:728-734. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19700247>.
347. Mahdavi A, Monk BJ, Ragazzo J, et al. Pelvic radiation improves local control after hysterectomy for uterine leiomyosarcoma: a 20-year experience. *Int J Gynecol Cancer* 2009;19:1080-1084. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19820372>.
348. Giuntoli RL, 2nd, Metzinger DS, DiMarco CS, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. *Gynecol Oncol* 2003;89:460-469. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12798712>.
349. Dusenbery KE, Potish RA, Judson P. Limitations of adjuvant radiotherapy for uterine sarcomas spread beyond the uterus. *Gynecol Oncol* 2004;94:191-196. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15262141>.
350. Ricci S, Giuntoli RL, 2nd, Eisenhauer E, et al. Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma? *Gynecol Oncol* 2013;131:629-633. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24016408>.
351. Hensley ML, Wathen JK, Maki RG, et al. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). *Cancer* 2013;119:1555-1561. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23335221>.
352. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma